Bienvenue au réseau de diffusion sur l'arthrite Arthritis Research Centre of Canada Arthritis Consumer Experts

Bonnes nouvelles pour le Ontario !

Le tofacitinib (Xeljanz®) est approuvé au Ontario dans le traitement de la polyarthrite rhumatoïde.

Girl in flight mid airDepuis le 17 juin dernier, le tofacitinib (Xeljanz®) a été ajouté à la liste des médicaments remboursés par le régime public d’assurance-médicaments du Ontario dans le traitement de la polyarthrite rhumatoïde, de modérée à sévère.

Le tofacitinib est un médicament à petite molécule cible administré par voie orale pour lequel Santé Canada a émis un Avis de conformité le 17 avril 2014. Le tofacitinib est indiqué en association avec la méthotrexate pour réduire les signes et symptômes de la polyarthrite rhumatoïde active, de modérée à sévère, chez les patients adultes ayant répondu de façon inadéquate à la méthotrexate. Pour les cas d’intolérance à la méthotrexate, le médecin peut envisager l’utilisation du tofacitinib en monothérapie.

Cliquez ici pour accéder à la version la plus à jour de la fiche-rapport du comité ACE sur le remboursement des modificateurs de la réponse biologique par les régimes publics d’assurance-médicaments.

Good news in Ontario!

Girl in flight mid airTofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis approved in Ontario.

As of June 17th, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Ontario’s drug formulary.

Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.

Click here to view the most up-to-date version of ACE’s Report Card on provincial formulary reimbursement listings for biologic response modifiers.

Expressions of Interest: Arthritis Research Ambassadors

Expressions of Interest: CIHR Institute of Musculoskeletal Health and Arthritis Research Ambassadors

Three people standing togetherThe Institute of Musculoskeletal Health and Arthritis of the Canadian Institutes of Health Research (CIHR – IMHA), is seeking applications to fill four vacancies in the CIHR – IMHA Research Ambassadors group. We specifically need representation from young adults, men, vulnerable populations, and representation of disease groups falling under our research mandate including conditions affecting bone, connective tissue, joint, muscle, oral health and skin.

WHO: Research Ambassadors are members of the public who live with, or advocate for others living with a condition that falls under CIHR – IMHA’s research mandate (conditions related to bones, joints, muscles, connective tissue, skin and teeth). Research Ambassadors bridge the gap between researchers and patients, addressing the different stages of the research process known as: Basic Biomedical Science, Clinical Science and Knowledge, and Clinical Practice and Health Decision Making.

WHAT: The main principles of what Research Ambassadors do are: Continue reading

EULAR: Updated recommendations for fibromyalgia

A woman deep in thought in the shadowThe European League Against Rheumatism (EULAR) has published updated recommendations on the management of fibromyalgia. The detailed recommendations can be found in the Annals of the Rheumatic Diseases.

Fibromyalgia is a condition characterized primarily by chronic widespread pain (CWP) in the muscles, ligaments and tendons, and a heightened sensitivity to touch resulting in pain that can last for months.

Common signs and symptoms of fibromyalgia include: Continue reading

Great news for ACE’s scientific advisor, Arthritis Research Canada

New Canadian Institutes of Health Research funding, awards, and promotions at Arthritis Research Canada will advance arthritis research, treatment and care

Two kids in the sun with hands held highACE’s scientific advisor, Arthritis Research Canada (ARC), has been awarded two Canadian Institutes of Health Research Knowledge to Action grants. Here are the names of the award recipients and a brief explanation of their research projects:

  • Dr. Deborah Marshall’s research, entitled “Building Partnerships to Improve Care of Early Knee Osteoarthritis Patients: Co-developing a Risk Management Tool” aims to develop a tool to help family physicians to motivate people with early osteoarthritis of the knee to institute life-style changes at a time when they can make a difference to the progress of the disease.
  • Dr. Paul Fortin’s research, entitled “Dissemination of the Lupus Interactive Navigator (LIN) – Measuring its Uptake and Impact on Global Health and Self-Care” will be devoted to developing an online tool to facilitate and support engagement, coping and self-management in people with lupus.

The following researchers at ARC have each been awarded a prestigious award from the science community: Continue reading

JointHealth™ insight: Nouvelles récentes sur les décisions…

…d’inclusion pour remboursement aux listes provinciales de médicaments

Nouvelles importantes pour les personnes atteintes de formes d’arthrite inflammatoire au Canada

Dans ce numéro du JointHealth™ insight, le comité ACE (Arthritis Consumer Experts) rend compte pour vous des toutes dernières nouvelles sur les décisions d’inclusion aux listes provinciales de médicaments. Il contient les renseignements à propos des modifications aux listes provinciales de médicaments assurés et leur impact sur les Canadiennes et Canadiens aux prises avec une forme d’arthrite inflammatoire. Ces modifications abordées dans cette mise à jour affectent directement les personnes atteintes de polyarthrite rhumatoïde (PR), de spondylarthrite ankylosante (SA), d’arthrite psoriasique (APs) et d’arthrite juvénile idiopathique (AJI).

Map of Canada in FrenchManitoba
Le médicament suivant a été ajouté à la liste des médicaments assurés par la province : Continue reading